Tumor Microenvironment and Drug Response: A Pathology–pharmacology Perspective on Mechanisms of Therapeutic Resistance

Abstract

Aims: To provide an integrated review of tumor microenvironment (TME) architecture and its influence on pharmacologic response, with emphasis on mechanisms of therapeutic resistance and translational implications for precision oncology. Study Design: Narrative review of peer-reviewed literature examining tumor microenvironment biology and therapeutic resistance mechanisms. Methodology: Literature was identified through systematic searches of PubMed, MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov using predefined keywords including “tumor microenvironment,” “drug resistance,” “hypoxia,” “immune checkpoint,” and “cancer stroma.” Approximately 120 relevant studies published between 2000 and 2024 were screened, and key mechanistic and translational studies were included for narrative synthesis. Results: The tumor microenvironment consists of cancer-associated fibroblasts, diverse immune infiltrates, extracellular matrix components, and structurally abnormal vasculature that collectively create physical and biological barriers to drug delivery and response. Stromal fibrosis elevates interstitial fluid pressure, limiting the diffusion of macromolecular therapeutics. Hypoxia stabilizes hypoxia-inducible factors, promoting survival signaling and conferring resistance to chemotherapy and radiotherapy. Immune checkpoint expression modifies response to immunotherapy in a context-dependent manner. Histopathological biomarkers—including Immunoscore, tumor mutational burden, and Hypoxia-inducible factor-1 alpha (HIF-1α) expression—serve as critical determinants in therapeutic stratification. Emerging combinatorial strategies targeting multiple TME components offer promising avenues for overcoming resistance. Conclusion: Therapeutic resistance is multidimensionally shaped by microenvironmental dynamics extending well beyond tumor cell-intrinsic genomic alterations. Integrating pathological evaluation with pharmacologic understanding is essential for advancing precision oncology strategies and supports genuinely interdisciplinary translational medicine.